Effects of Linagliptin and Pioglitazone on Fracture Healing in an Experimental Type 2 Diabetes Rat Model

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 Dec 8

PMID 36479259

Authors

Hamisi M Mraja

Sever Caglar

Muhammed Uslu

Bilal Yilmaz

Mustafa Fatih Dasci

Elif Yaprak Sarac

Metehan Demirkol

Affiliations

Soon will be listed here.

Abstract

Aim: Our study aimed to examine the effects of Linagliptin, Pioglitazone, and their combination on fracture healing in a diabetes rat femur fracture model.

Material And Methods: Type 2 diabetes mellitus (T2DM) induced rats were randomly divided into four groups: non-treated diabetes group (TD), Pioglitazone group (P), Linagliptin group (L), and Pioglitazone and Linagliptin group (PL). Daily oral dosage of pioglitazone (10 mg/kg/day), linagliptin (10 mg/kg/day), and their combination were administered. Femur fractures were stabilized intramedullary. At weeks 2 and 6, rats were sacrificed for evaluation radiologically, biomechanically, histopathologically, histomorphometrically, and immunohistochemically.

Results: Flexural strength of the L and PL groups were significantly higher compared to the P group. The highest healing score was in the L group and lowest in the P group, while the highest inflammation score was in the P group and lowest in the L group. A cluster of differentiation (CD) CD 34 reactivity was highest in the L group and lowest in the PL group.

Conclusion: Linagliptin treatment significantly increased histological healing scores, callus volume, biomechanical strength, and vascularity, however, minimized the inflammatory process, which was increased by pioglitazone. The combination of linagliptin and pioglitazone restored BMD and increased biomechanical strength. Linagliptin monotherapy is rarely indicated; hence, T2DM patients with a high risk of bone fractures can be considered for combined therapy of pioglitazone and linagliptin.

References

de Liefde I, van der Klift M, de Laet C, van Daele P, Hofman A, Pols H . Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005; 16(12):1713-20. DOI: 10.1007/s00198-005-1909-1. View

Tsiridis E, Upadhyay N, Giannoudis P . Molecular aspects of fracture healing: which are the important molecules?. Injury. 2007; 38 Suppl 1:S11-25. DOI: 10.1016/j.injury.2007.02.006. View

van Raalte D, van Genugten R, Eliasson B, Moller-Goede D, Mari A, Tura A . The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014; 170(4):565-74. DOI: 10.1530/EJE-13-0639. View

Jiang G, Matsumoto H, Hori M, Gunji A, Hakozaki K, Akimoto Y . Correlation among geometric, densitometric, and mechanical properties in mandible and femur of osteoporotic rats. J Bone Miner Metab. 2008; 26(2):130-7. DOI: 10.1007/s00774-007-0811-7. View

Askov-Hansen C, Jeppesen P, Lund P, Hartmann B, Holst J, Henriksen D . Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure. Regul Pept. 2012; 181:4-8. DOI: 10.1016/j.regpep.2012.11.002. View

Morgan E, Mason Z, Chien K, Pfeiffer A, Barnes G, Einhorn T . Micro-computed tomography assessment of fracture healing: relationships among callus structure, composition, and mechanical function. Bone. 2008; 44(2):335-44. PMC: 2669651. DOI: 10.1016/j.bone.2008.10.039. View

Drucker D, Nauck M . The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368(9548):1696-705. DOI: 10.1016/S0140-6736(06)69705-5. View

Park S, OConnor K, Sung R, McKellop H, Sarmiento A . Comparison of healing process in open osteotomy model and closed fracture model. J Orthop Trauma. 1999; 13(2):114-20. DOI: 10.1097/00005131-199902000-00008. View

Schwartz A, Chen H, Ambrosius W, Sood A, Josse R, Bonds D . Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study. J Clin Endocrinol Metab. 2015; 100(11):4059-66. PMC: 4702444. DOI: 10.1210/jc.2015-1215. View

10.

Facchini D, Yuen V, Battell M, McNeill J, Grynpas M . The effects of vanadium treatment on bone in diabetic and non-diabetic rats. Bone. 2005; 38(3):368-77. DOI: 10.1016/j.bone.2005.08.015. View

11.

Yang Y, Zhao C, Liang J, Yu M, Qu X . Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms. Front Pharmacol. 2017; 8:487. PMC: 5524773. DOI: 10.3389/fphar.2017.00487. View

12.

Kanczler J, Oreffo R . Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater. 2008; 15:100-14. DOI: 10.22203/ecm.v015a08. View

13.

Kim S, Baik S, Yoon K, Lee H, Filozof C . Efficacy and safety of vildagliptin/pioglitazone combination therapy in Korean patients with diabetes. World J Diabetes. 2011; 1(5):153-60. PMC: 3083898. DOI: 10.4239/wjd.v1.i5.153. View

14.

Lin Y, Sun Z . Current views on type 2 diabetes. J Endocrinol. 2009; 204(1):1-11. PMC: 2814170. DOI: 10.1677/JOE-09-0260. View

15.

Loke Y, Singh S, Furberg C . Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2008; 180(1):32-9. PMC: 2612065. DOI: 10.1503/cmaj.080486. View

16.

Refaat R, Sakr A, Salama M, El Sarha A . Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats. Drug Dev Res. 2016; 77(6):300-9. DOI: 10.1002/ddr.21324. View

17.

McDonough A, Rosenthal R, Cao X, Saag K . The effect of thiazolidinediones on BMD and osteoporosis. Nat Clin Pract Endocrinol Metab. 2008; 4(9):507-13. DOI: 10.1038/ncpendmet0920. View

18.

Eom Y, Gwon A, Kwak K, Kim J, Yu S, Lee S . Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats. PLoS One. 2016; 11(12):e0168569. PMC: 5172620. DOI: 10.1371/journal.pone.0168569. View

19.

Mayr-Wohlfart U, Waltenberger J, HAUSSER H, Kessler S, Gunther K, Dehio C . Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone. 2002; 30(3):472-7. DOI: 10.1016/s8756-3282(01)00690-1. View

20.

Rosenstock J, Kim S, Baron M, Camisasca R, Cressier F, Couturier A . Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007; 9(2):175-85. DOI: 10.1111/j.1463-1326.2006.00698.x. View